Lutein and zeaxanthin are carotenoids (plant pigments) that build up in the retina, the part of the eye damaged by age-related macular degeneration (AMD). Unlike beta-carotene, the body does not turn them into vitamin A. As supplements they are used mainly for eye health, and they are part of the AREDS2 eye vitamin formula.
Also known as: zeaxanthin, AREDS2 formula, macular carotenoids.
Lutein has no RDA or upper limit. The AREDS2 trial used 10 mg of lutein with 2 mg of zeaxanthin a day for a median of 5 years. These are study protocols, not a recommendation.
It is sold in the US as a dietary supplement. Under the 1994 dietary supplement law (DSHEA), FDA does not approve dietary supplements before they are marketed, and the maker, not FDA, is responsible for safety and labeling.
In AREDS2, an NIH trial of 4,203 people aged 50 to 85 at risk of advanced AMD, adding lutein and zeaxanthin to the AREDS eye vitamin formula did not lower progression to advanced AMD in the main analysis. ODS adds that people with the lowest dietary intake of lutein and zeaxanthin had a 26% lower risk of advanced AMD when they took them, and that the formula with lutein and zeaxanthin instead of beta-carotene lowered risk by 18% compared with the beta-carotene version. More lung cancers were seen with beta-carotene, mostly in former smokers, so the AREDS2 investigators said lutein and zeaxanthin could replace it; 10-year follow-up supported the swap (ODS).
A part of AREDS2 that tested memory and thinking in 3,501 older adults found no effect of lutein and zeaxanthin (Chew 2015). If you have or are developing AMD, ODS advises talking with your health care provider about the AREDS formulas.
We could not find a single published half-life or time to peak for lutein that applies to a supplement dose, so we do not list one.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator